We are live on ! Find out more
XBI icon

State Street SPDR S&P Biotech ETF

769 hedge funds and large institutions have $10.2B invested in State Street SPDR S&P Biotech ETF in 2024 Q3 according to their latest regulatory filings, with 88 funds opening new positions, 240 increasing their positions, 270 reducing their positions, and 73 closing their positions.

New
Increased
Maintained
Reduced
Closed

21% more first-time investments, than exits

New positions opened: 88 | Existing positions closed: 73

17% more funds holding in top 10

Funds holding in top 10: 1821 (+3)

11% more capital invested

Capital invested by funds: $9.17B → $10.2B (+$994M)

1.23% more ownership

Funds ownership: 128.67%129.89% (+1.2%)

1% more funds holding

Funds holding: 761769 (+8)

11% less repeat investments, than reductions

Existing positions increased: 240 | Existing positions reduced: 270

16% less call options, than puts

Call options by funds: $2.8B | Put options by funds: $3.33B

Holders
769
Holders Change
+8
Holders Change %
+1.05%
% of All Funds
11.04%
Holding in Top 10
21
Holding in Top 10 Change
+3
Holding in Top 10 Change %
+16.67%
% of All Funds
0.3%
New
88
Increased
240
Reduced
270
Closed
73
Calls
$2.8B
Puts
$3.33B
Net Calls
-$526M
Net Calls Change
+$836M
Name Holding Trade Value Shares
Change
Change in
Stake
PCA
526
Peddock Capital Advisors
Massachusetts
$302K +$300K +3,057 New
MSS
527
Mitchell Sinkler & Starr
Pennsylvania
$299K +$84.5K +860 +40%
JJBC
528
James J. Burns & Company
New York
$299K +$4.81K +49 +2%
AWA
529
Amplius Wealth Advisors
Pennsylvania
$297K +$98 +1 +0%
FFAM
530
Forge First Asset Management
Canada
$296K +$295K +3,000 New
CC
531
Courier Capital
New York
$296K -$12.3K -125 -4%
PCM
532
Ping Capital Management
New York
$296K
FLC
533
Fifth Lane Capital
Texas
$296K +$295K +3,000 New
PHK
534
Point72 Hong Kong
Hong Kong
$296K +$295K +3,000 New
EBA
535
Eagle Bay Advisors
New York
$294K
SI
536
Stephens Inc
Arkansas
$294K -$289K -2,940 -50%
Lido Advisors
537
Lido Advisors
California
$294K +$19.6K +199 +7%
IPAM
538
Investment Partners Asset Management
New Jersey
$289K +$3.05K +31 +1%
VVP
539
Venture Visionary Partners
Ohio
$288K +$98 +1 +0%
PTC
540
Private Trust Company
Ohio
$288K +$237K +2,410 +476%
HW
541
Hamilton Wealth
California
$287K +$285K +2,900 New
TWP
542
Tempus Wealth Planning
California
$281K +$1.67K +17 +0.6%
CAM
543
Covenant Asset Management
New Jersey
$281K
MYIA
544
Mount Yale Investment Advisors
Colorado
$281K +$30.9K +315 +12%
I
545
INVST
Indiana
$277K +$15.7K +160 +6%
PCM
546
Poehling Capital Management
Wisconsin
$273K -$21.1K -215 -7%
FFA
547
Fragasso Financial Advisors
Pennsylvania
$273K -$4.03K -41 -1%
SDAM
548
Shulman DeMeo Asset Management
New York
$272K -$82.4K -839 -23%
IAS
549
Insigneo Advisory Services
Florida
$272K +$30.3K +308 +13%
GL
550
Graypoint LLC
New York
$271K +$14.3K +146 +6%

XBI Hedge Fund Activity: Q3 2024 in Review

769 of the 6,964 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Biotech ETF (XBI) for Q3 2024, worth a combined $10.2B — up 11% from $9.17B a quarter earlier.

Buyers outnumbered sellers: 88 funds opened new XBI positions and 73 closed out — a net gain of 15 holders — while 240 added to existing stakes and 270 trimmed.

The largest buyer was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, adding an estimated $603M. The largest seller was Avoro Capital Advisors, exiting entirely with an estimated $281M sold.

  • 769 institutional investors held State Street SPDR S&P Biotech ETF (XBI) as of Q3 2024, up from 761 in Q2 2024.
  • Funds reported $10.2B of State Street SPDR S&P Biotech ETF stock for Q3 2024, up 11% quarter-over-quarter.
  • 88 funds opened new State Street SPDR S&P Biotech ETF positions in Q3 2024 and 73 closed out, a net change of +15 holders.
  • The largest State Street SPDR S&P Biotech ETF buyer in Q3 2024 was Healthcare of Ontario Pension Plan (HOOPP) Trust Fund, an estimated $603M added.
  • The largest State Street SPDR S&P Biotech ETF seller in Q3 2024 was Avoro Capital Advisors, an estimated $281M sold.

Based on aggregated 13F filings for Q3 2024.